Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
A phase 3 trial of Trilaciclib in small-cell lung cancer, run by Pharmacosmos A/S, now recruiting.
Overview
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07473128 by Pharmacosmos A/S, with 120 participants planned, started 2026-06-30 and due to reach its primary completion in 2027-06. Interventions recorded: Trilaciclib, Saline (0.9% NaCl). Conditions listed: Limited Stage Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Setting
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer
Phase
Phase 3
Sponsor
Pharmacosmos A/S
Registry
Enrolled
120
Similar pages
not linked directly; found by shared links- CompanyG1 Therapeutics
Shares Trilaciclib, Small-cell lung cancer.
- TreatmentTopotecan
Shares Trilaciclib, Small-cell lung cancer.